Avedro, Inc. (AVDR)
| Market Cap | 402.80M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jan 6, 2020 |
| Last Price | $22.99 |
| Previous Close | $22.99 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 22.99 - 22.99 |
| Day's Volume | 0 |
| 52-Week Range | 10.75 - 27.51 |
News
There are no news available yet.
About AVDR
Avedro, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used fo... [Read more...]
| Industry Medical Specialties | IPO Date Feb 14, 2019 |
| CEO Reza Zadno | Employees 122 |
| Stock Exchange NASDAQ | Ticker Symbol AVDR |
Financial Performance
In 2018, Avedro's revenue was $27.67 million, an increase of 37.30% compared to the previous year's $20.15 million. Losses were -$25.12 million, 18.1% more than in 2017.